| Literature DB >> 35413834 |
Mehjar Azzouz1, Yiyi Xu2, Lars Barregard2, Björn Fagerberg3, Bengt Zöller4, Peter Molnár2,5, Anna Oudin6,7, Mårten Spanne8, Gunnar Engström9, Leo Stockfelt2,5.
Abstract
INTRODUCTION: Air pollution is associated with increased risk of cardiovascular disease, possibly through chronic systemic inflammation that promotes the progression of atherosclerosis and the risk of cardiovascular events. This study aimed to investigate the associations between air pollution and established biomarkers of inflammation and cardiovascular disease.Entities:
Keywords: Air pollution; Biomarkers; C-reactive protein; Cardiovascular disease; Inflammation; Particulate matter
Mesh:
Substances:
Year: 2022 PMID: 35413834 PMCID: PMC9004064 DOI: 10.1186/s12940-022-00851-1
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Fig. 1The distribution of PM2.5 in the Malmö area in 1992, in μg/m3
Characteristics of study population, exposure levels and biomarker levels at recruitment
| All | Missing | |
|---|---|---|
| Age, years (mean, SD) | 57.5 (5.9) | 1 |
| Sex (n (%)) | 0 | |
| Men | 2572 (42%) | |
| Women | 3531 (57%) | |
| Alcohol, g (mean, SD) | 10.4 (12.5) | 323 |
| Smoking status (n (%)) | 315 | |
| Regular | 1347 (23%) | |
| Occasional | 273 (5%) | |
| Previous smoker | 1915 (33%) | |
| Never smoker | 2253 (39%) | |
| Number of cigarettes per day for regular and occasional smokers only (mean, SD) | 14 (9) | 185 |
| Physical activity score (mean, SD) | 8137 (5923) | 366 |
| Living alone vs with partner (n (%)) | 315 | |
| Living alone | 1345 (23%) | |
| With partner | 4443 (77%) | |
| Country of birth (n (%)) | 314 | |
| Sweden | 5125 (89%) | |
| Outside of Sweden | 664 (12%) | |
| Area Income 1994, Euro (mean, SD) | 13,830 (3047) | 33 |
| Education (n (%)) | 322 | |
| Low (< 9) | 2676 (47%) | |
| Moderate | 1982 (34%) | |
| High (> 12) | 1123 (19%) | |
| Occupation (n (%)) | 355 | |
| Blue collar | 2241 (39%) | |
| White collar | 2906 (51%) | |
| Others | 601 (11%) | |
| Systolic blood pressure mmHg (mean, SD) | 141 (19) | 1 |
| Diabetes (n (%)) | 0 | |
| Yes | 293 (5%) | |
| No | 5810 (95%) | |
| CVD (n (%)) | 0 | |
| Yes | 151 (2%) | |
| No | 5951 (98%) | |
| BMIa, kg/m2 (mean, SD) | 25.8 (4) | 8 |
| Apo-B/Apo-A1 (mean, SD) | 0.7 (0.2) | 204 |
| Statin use (n (%)) | 0 | |
| Yes | 28 (0.5%) | |
| No | 6075 (99.5%) | |
| NSAID use (n (%)) | 0 | |
| Yes | 63 (1%) | |
| No | 6040 (99%) | |
| Total PM10, μg/m3 (mean, SD) | 14.9 (1.7) | 46 |
| Total PM2.5, μg/m3 (mean, SD) | 10.5 (0.8) | 46 |
| Total PM coarse, μg/m3 (mean, SD) | 4.4 (1.1) | 46 |
| Total NOx μg/m3 (mean, SD) | 39.1 (13.8) | 46 |
| PM10 traffic, μg/m3 (mean, SD) | 2.8 (1.3) | 46 |
| PM10 non-traffic, μg/m3 (mean SD) | 0.9 (0.2) | 46 |
| Leukocytes, # cells × 109/L (median, p5 – p95) | 5.9 (3.9–9) | 18 |
| NLR (median, p5 – p95)b | 2 (1.1–3.7) | 36 |
| CRP, mg/L (median, p5 – p95)c | 1.4 (0.3–8.4) | 799 |
| SuPAR, ng/ml (median, p5 – p95) | 2.8 (1.9–4.8) | 838 |
| Lp-PLA2, ng/ml (median, p5 – p95) | 256 (157–415) | 710 |
| Ceruloplasmin, g/L (median, p5 – p95) | 0.49 (0.35–0.73) | 1248 |
| Orosomucoid, g/L (median, p5 – p95) | 0.7 (0.4–1.1) | 970 |
| Haptoglobin, g/L (median, p5 – p95) | 1.3 (0.5–2.3) | 1412 |
| C3, g/L (median, p5 – p95) | 1.51 (1.1–2.2) | 909 |
| Alpha-1-antitrypsin, g/L (median, p5 – p95) | 1.2 (0.8–1.7) | 1005 |
Means are presented with SD, medians with a 5–95% range and counts with percentages of subjects
aBody Mass Index
bNeutrophil-lymphocyte ratio
cMedian of CRP was 1.4 mg/L
Association between total PM2.5, PM10 as well as NOx exposure and biomarkers
| PM2.5 | PM10 | NOx | |||||
|---|---|---|---|---|---|---|---|
| Increment of exposure | 5 μg/m3 | 5 μg/m3 | 20 μg/m3 | ||||
| β-Coefficient (95% CI) | β-Coefficient (95% CI) | P value* | β-Coefficient (95% CI) | P value* | |||
| Leukocytes | M0 | −0.021 (− 0.064–0.022) | 0.34 | 0.017 (− 0.0023–0.036) | 0.084 | ||
| M1 | −0.02 (− 0.062–0.021) | 0.33 | 0.0004 (− 0.018–0.019) | 0.97 | 0.0024 (− 0.0067–0.011) | 0.61 | |
| M2 | − 0.095 (− 0.38–0.19) | 0.52 | −0.0062 (− 0.026–0.014) | 0.55 | −0.0022 (− 0.012–0.0078) | 0.67 | |
| NLR | M0 | 0.0098 (− 0.004–0.024) | 0.17 | ||||
| M1 | 0.023 (− 0.0062–0.053) | 0.12 | 0.0062 (− 0.0081–0.021) | 0.4 | |||
| M2 | 0.03 (− 0.0031–0.062) | 0.076 | 0.0074 (− 0.0089–0.024) | 0.37 | |||
| CRP | M0 | −0.0438 (− 0.2361–0.1485) | 0.655 | 0.047 (− 0.04–0.13) | 0.29 | 0.035 (− 0.0065–0.077) | 0.097 |
| M1 | 0.0621 (− 0.1216–0.2459) | 0.507 | 0.038 (− 0.045–0.12) | 0.37 | 0.015 (− 0.025–0.055) | 0.46 | |
| M2 | 0.0393 (− 0.1502–0.2288) | 0.684 | 0.0034 (− 0.087–0.094) | 0.94 | −0.0075 (− 0.053–0.038) | 0.74 | |
| SuPAR | M0 | − 0.023 (− 0.0755–0.0294)’ | 0.389 | 0.022 (− 0.0012–0.045) | 0.063 | ||
| M1 | −0.0173 (− 0.067–0.0323) | 0.494 | 0.0053 (− 0.017–0.027) | 0.64 | 0.0062 (− 0.0045–0.017) | 0.26 | |
| M2 | −0.0199 (− 0.0704–0.0306) | 0.441 | −0.0024 (− 0.026–0.022) | 0.84 | 0.0019 (− 0.01–0.014) | 0.76 | |
| LP-PLA2 | M0 | 0.019 (− 0.0046–0.043) | 0.11 | 0.00086 (− 0.011–0.012) | 0.88 | ||
| M1 | 0.011 (− 0.014–0.035) | 0.39 | −0.0045 (− 0.016–0.0071) | 0.45 | |||
| M2 | 0.017 (− 0.009–0.043) | 0.2 | −0.00027 (− 0.013–0.013) | 0.97 | |||
| Ceruloplasmin | M0 | 0.0082 (− 0.00056–0.017) | 0.067 | ||||
| M1 | 0.0072 (− 0.0017–0.016) | 0.11 | |||||
| M2 | 0.0025 (− 0.0075–0.012) | 0.62 | |||||
| Orosomucoid | M0 | 0.0082 (− 0.0035–0.02) | 0.17 | ||||
| M1 | 0.004 (− 0.0074–0.015) | 0.49 | |||||
| M2 | − 0.00097 (− 0.014–0.012) | 0.88 | |||||
| Haptoglobin | M0 | ||||||
| M1 | 0.038 (− 0.0004–0.077) | 0.058 | 0.013 (− 0.0059–0.032) | 0.18 | |||
| M2 | 0.026 (− 0.016–0.069) | 0.23 | 0.0043 (− 0.017–0.025) | 0.69 | |||
| C3 | M0 | 0.0064 (− 0.0023–0.015) | 0.15 | ||||
| M1 | 0.0066 (− 0.0015–0.015) | 0.11 | |||||
| M2 | 0.00048 (− 0.0085–0.0095) | 0.92 | |||||
| alpha-1-antitrypsin | M0 | ||||||
| M1 | 0.007 (− 0.0029–0.017) | 0.17 | |||||
| M2 | 0.00042 (− 0.011–0.012) | 0.94 |
*p < 0.05 bolded. M0: adjusted for age and sex. M1: adjusted for age, sex, alcohol consumption, BMI, smoking status, and education. M2: adjusted for age, sex, alcohol consumption, BMI, smoking status, education, number of cigarettes, mean area income, occupational class, leisure-time physical activity, systolic blood pressure, Apo-B/Apo-A1 ratio, prevalent diabetes, country of birth, cohabitation, statin use and NSAID use
Association between PM coarse, PM10 traffic and PM10 non-traffic exposure and biomarkers
| PM coarse | PM10 traffic | PM10 non-traffic | |||||
|---|---|---|---|---|---|---|---|
| Increment of exposure | 5 μg/m3 | 1 μg/m3 | 1 μg/m3 | ||||
| β-Coefficient (95% CI) | P value* | β-Coefficient (95% CI) | P value* | β-Coefficient (95% CI) | P value* | ||
| Leukocytes | M0 | 0.01 (− 0.016–0.036) | 0.27 | 0.0067 (− 0.033–0.046) | 0.74 | ||
| M1 | 0.01 (− 0.018–0.038) | 0.47 | 0.0012 (− 0.0034–0.0059) | 0.6 | −0.0064 (− 0.044–0.031) | 0.74 | |
| M2 | − 0.0031 (− 0.034–0.028) | 0.85 | − 0.0013 (− 0.0065–0.004) | 0.64 | −0.013 (− 0.052–0.025) | 0.5 | |
| NLR | M0 | 0.034 (− 0.0089–0.077) | 0.12 | 0.005 (− 0.0022–0.012) | 0.17 | 0.027 (− 0.031–0.085) | 0.36 |
| M1 | 0.023 (− 0.022–0.067) | 0.32 | 0.0031 (− 0.0042–0.011) | 0.41 | 0.011 (− 0.049–0.07) | 0.73 | |
| M2 | 0.031 (− 0.02–0.081) | 0.24 | 0.0039 (− 0.0046–0.012) | 0.37 | 0.0057 (− 0.057–0.069) | 0.86 | |
| CRP | M0 | 0.13 (− 0.004–0.26) | 0.058 | 0.019 (− 0.0024–0.041) | 0.082 | −0.086 (− 0.26–0.087) | 0.33 |
| M1 | 0.057 (− 0.067–0.182) | 0.37 | 0.0057 (− 0.015–0.026) | 0.59 | 0.0017 (− 0.16–0.17) | 0.98 | |
| M2 | −0.014 (− 0.15–0.13) | 0.85 | −0.0074 (− 0.031–0.016) | 0.54 | −0.046 (− 0.22–0.13) | 0.61 | |
| SuPAR | M0 | −0.017 (− 0.064–0.03) | 0.48 | ||||
| M1 | 0.019 (− 0.014–0.053) | 0.25 | 0.0039 (− 0.0016–0.0093) | 0.17 | −0.0089 (− 0.053–0.035) | 0.69 | |
| M2 | 0.0048 (− 0.032–0.042) | 0.8 | 0.0016 (− 0.0045–0.0077) | 0.61 | −0.011 (− 0.057–0.034) | 0.63 | |
| LP-PLA2 | M0 | 0.0028 (− 0.033–0.038) | 0.88 | 0.0008 (− 0.0052–0.0067) | 0.8 | 0.0056 (− 0.042–0.053) | 0.82 |
| M1 | −0.015 (− 0.051–0.021) | 0.42 | −0.0023 (− 0.0083–0.0036) | 0.44 | 0.0051 (− 0.043–0.053) | 0.84 | |
| M2 | − 0.0053 (− 0.046–0.035) | 0.8 | −0.0003 (− 0.007–0.0065) | 0.94 | 0.026 (− 0.024–0.076) | 0.31 | |
| Ceruloplasmin | M0 | 0.0042 (− 0.0003–0.0087) | 0.065 | 0.035 (− 0.0014–0.072) | 0.06 | ||
| M1 | 0.0035 (− 0.001–0.0081) | 0.13 | |||||
| M2 | 0.024 (− 0.0071–0.055) | 0.13 | 0.001 (− 0.0042–0.0061) | 0.71 | 0.026 (− 0.013–0.065) | 0.18 | |
| Orosomucoid | M0 | 0.012 (− 0.0031–0.027) | 0.12 | 0.032 (− 0.016–0.081) | 0.19 | ||
| M1 | 0.03 (− 0.0054–0.065) | 0.097 | 0.002 (− 0.0038–0.0079) | 0.5 | |||
| M2 | 0.017 (− 0.022–0.056) | 0.39 | −0.0013 (− 0.017–0.015) | 0.87 | 0.046 (− 0.0032–0.095) | 0.067 | |
| Haptoglobin | M0 | 0.026 (− 0.053–0.11) | 0.52 | ||||
| M1 | 0.038 (− 0.02–0.096) | 0.2 | 0.006 (− 0.0036–0.016) | 0.22 | 0.029 (− 0.049–0.11) | 0.46 | |
| M2 | 0.011 (− 0.055–0.076) | 0.75 | 0.0014 (− 0.0095–0.012) | 0.8 | 0.013 (− 0.069–0.094) | 0.76 | |
| C3 | M0 | 0.0037 (− 0.0007–0.0081) | 0.1 | 0.0047 (− 0.032–0.041) | 0.8 | ||
| M1 | 0.0032 (− 0.001–0.0074) | 0.14 | 0.033 (− 0.0008–0.067) | 0.055 | |||
| M2 | 0.016 (− 0.012–0.044) | 0.26 | −0.0001 (− 0.0048–0.0045) | 0.96 | 0.022 (− 0.013–0.057) | 0.21 | |
| alpha-1-antitrypsin | M0 | 0.035 (− 0.0059–0.076) | 0.094 | ||||
| M1 | 0.0036 (− 0.0015–0.0087) | 0.17 | 0.032 (−0.0086–0.074) | 0.12 | |||
| M2 | 0.014 (−0.021–0.049) | 0.44 | −0.0001 (− 0.006–0.0057) | 0.97 | 0.019 (− 0.025–0.062) | 0.39 | |
*p < 0.05 bolded. M0: adjusted for age and sex. M1: adjusted for age, sex, alcohol consumption, BMI, smoking status, and education. M2: adjusted for age, sex, alcohol consumption, BMI, smoking status, education, number of cigarettes, mean area income, occupational class, leisure-time physical activity, systolic blood pressure, ApoA/ApoB1 ratio, prevalent diabetes, country of birth, cohabitation, statin use and NSAID use